Related Experiment Videos
Acinetobacter infection in the ICU
Clinton K Murray1, Duane R Hospenthal
1Infectious Disease Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA. clinton.murray@amedd.army.mil
Abstract:
Acinetobacter is a formidable challenge to managing critically ill patients. This pathogen's ability to rapidly develop antimicrobial resistance to all currently available antimicrobial agents is concerning because increasing data support attributable mortality to these bacteria when associated with hospitalized patients with comorbidities and severe illness. The role of dual therapy is currently unclear and might be associated with increased toxicities without proven synergy or ability to prevent the development of resistance. Infection control and antibiotic control measures might have the greatest impact on these bacteria. Continued efforts are needed to develop new antimicrobial agents against this pathogen and assess the ideal currently available agents.
Insights
Acinetobacter infections pose a significant threat to critically ill patients due to rapid antimicrobial resistance. Effective management may rely on infection control and antibiotic stewardship, rather than dual therapy, to combat these challenging bacteria.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Microbiology
Background:
- Acinetobacter poses a significant challenge in managing critically ill patients.
- Rapid development of antimicrobial resistance by Acinetobacter is a growing concern.
- Increasing data link Acinetobacter infections to mortality in hospitalized patients with comorbidities.
Purpose of the Study:
- To evaluate the current understanding of Acinetobacter management in critically ill patients.
- To assess the role and potential drawbacks of dual antimicrobial therapy.
- To highlight effective strategies for controlling Acinetobacter infections.
Main Methods:
- Review of current literature on Acinetobacter infections and antimicrobial resistance.
- Analysis of the evidence regarding dual therapy efficacy and toxicity.
- Evaluation of infection control and antibiotic stewardship practices.
Main Results:
- Acinetobacter's rapid antimicrobial resistance development is a major clinical challenge.
- The role of dual therapy is unclear, potentially increasing toxicity without proven benefit.
- Infection control and antibiotic stewardship appear crucial for managing Acinetobacter.
Conclusions:
- Infection control and antibiotic stewardship are likely the most impactful strategies against Acinetobacter.
- Further research is needed to develop new antimicrobial agents.
- Optimal use of existing antimicrobial agents requires further assessment.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Acute Respiratory Failure-IV
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-III